NAYA Biosciences | 10-Q: Q3 2024 Earnings Report
NAYA Biosciences | 10-Q/A: Quarterly report (Amendment)
NAYA Biosciences | 10-K/A: Annual report (Amendment)
INVO Bioscience | 8-K: INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
INVO Bioscience | 10-Q: Q2 2024 Earnings Report
INVO Bioscience | 8-K: INVO Reports Record First Quarter 2024 Financial Results 353% Revenue Growth with improvement in Adjusted EBITDA
INVO Bioscience | 10-Q: Q1 2024 Earnings Report
INVO Bioscience | 10-K/A: Annual report (Amendment)
INVO Bioscience | 10-K/A: Annual report (Amendment)
INVO Bioscience | 8-K: INVO Reports Fourth Quarter and Full Year 2023 Financial Results
INVO Bioscience | 10-K: FY2023 Annual Report
INVO Bioscience | 10-K/A: Annual report (Amendment)
INVO Bioscience | 8-K: INVO Reports Record Third Quarter 2023 Financial Results Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with
INVO Bioscience | 10-Q: Q3 2023 Earnings Report
INVO Bioscience | 8-K: INVO Reports Second Quarter 2023 Financial Results Company to Host Conference Call Today at 4:30pm ET
INVO Bioscience | 10-Q: Q2 2023 Earnings Report
INVO Bioscience | 8-K: INVO Reports First Quarter 2023 Financial Results Company to Host Conference Call Today at 4:30pm ET
INVO Bioscience | 10-Q: Q1 2023 Earnings Report
INVO Bioscience | 10-K/A: Annual report (Amendment)
INVO Bioscience | 8-K: INVO Reports Fourth Quarter and Full Year 2022 Financial Results Company to Host Conference Call Today at 4:30pm ET
No Data